NASDAQ:TTOO T2 Biosystems (TTOO) Stock Forecast, Price & News $0.18 -0.02 (-9.96%) (As of 09/27/2023 ET) Add Compare Share Share Today's Range$0.17▼$0.2250-Day Range$0.09▼$0.5952-Week Range$0.05▼$5.72Volume71.03 million shsAverage Volume48.94 million shsMarket Capitalization$60.34 millionP/E RatioN/ADividend YieldN/APrice Target$2.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media T2 Biosystems MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside1,282.0% Upside$2.50 Price TargetShort InterestHealthy7.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.05Based on 11 Articles This WeekInsider TradingSelling Shares$5.75 M Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.99 out of 5 starsMedical Sector648th out of 976 stocksSurgical & Medical Instruments Industry68th out of 100 stocks 3.0 Analyst's Opinion Consensus RatingT2 Biosystems has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.50, T2 Biosystems has a forecasted upside of 1,282.0% from its current price of $0.18.Amount of Analyst CoverageT2 Biosystems has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted7.11% of the outstanding shares of T2 Biosystems have been sold short.Short Interest Ratio / Days to CoverT2 Biosystems has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in T2 Biosystems has recently decreased by 3.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldT2 Biosystems does not currently pay a dividend.Dividend GrowthT2 Biosystems does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TTOO. Previous Next 1.1 News and Social Media Coverage News SentimentT2 Biosystems has a news sentiment score of -0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for T2 Biosystems this week, compared to 2 articles on an average week.Search InterestOnly 107 people have searched for TTOO on MarketBeat in the last 30 days. This is a decrease of -55% compared to the previous 30 days.MarketBeat FollowsOnly 48 people have added T2 Biosystems to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, T2 Biosystems insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,750,006.00 in company stock.Percentage Held by InsidersOnly 0.10% of the stock of T2 Biosystems is held by insiders.Percentage Held by InstitutionsOnly 3.74% of the stock of T2 Biosystems is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here About T2 Biosystems (NASDAQ:TTOO) StockT2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2Dx Instrument, a bench-top instrument that runs various diagnostic tests from patient samples; T2Candida panel, a direct-from-blood test that identifies blood stream infections that causes sepsis and candidemia; T2Bacteria panel, a direct-from-blood test, which detects bacterial pathogens associated with sepsis; T2Resistance panel, a direct-from-blood test that identifies carbapenem resistance genes; and T2SARS-CoV-2 panel to detect SARS-CoV-2 virus. In addition, it is developing T2Biothreat panel for detection of biothreat pathogens; comprehensive sepsis panel to detect bloodstream infections caused by bacterial and Candida species, and antibiotic resistant markers; T2Cauris panel to provide direct detection of the emerging superbug Candida auris in patient skin, patient blood, and hospital environmental samples; and T2Lyme panel, a direct-from-blood test panel designed to run on the T2Dx Instrument to identify the bacteria that cause Lyme disease. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.Read More TTOO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TTOO Stock News HeadlinesSeptember 27, 2023 | msn.comCR Group sells another $1.3M shares in T2 Biosystems, shares fallSeptember 26, 2023 | americanbankingnews.comGroup L.P. Cr Sells 6,338,211 Shares of T2 Biosystems, Inc. (NASDAQ:TTOO) StockSeptember 27, 2023 | UNKNOWN (Ad)A Bio-Tech Stock That Has Been Growing Like Crazy!Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn MoreSeptember 26, 2023 | americanbankingnews.comT2 Biosystems, Inc. (NASDAQ:TTOO) Major Shareholder Group L.P. Cr Sells 6,338,211 Shares of StockSeptember 25, 2023 | benzinga.comWhat's Going On With T2 Biosystems Stock Today?September 23, 2023 | americanbankingnews.comGroup L.P. Cr Sells 10,401,466 Shares of T2 Biosystems, Inc. (NASDAQ:TTOO) StockSeptember 22, 2023 | benzinga.com10% Owner of T2 Biosystems Makes $3.81M SaleSeptember 22, 2023 | msn.comT2 Biosystems stock falls again as diagnostics developer faces cash crunch (update)September 27, 2023 | UNKNOWN (Ad)A Bio-Tech Stock That Has Been Growing Like Crazy!Recent News for This One Bio-Tech Has Us All Getting Excited. Sign Up today And Learn MoreSeptember 20, 2023 | msn.comT2 Biosystems’ stock extends losing streak despite FDA approval for anthrax and plague diagnostic testSeptember 20, 2023 | msn.comT2 Biosystems stock falls again as diagnostics developer faces cash crunchSeptember 20, 2023 | americanbankingnews.comT2 Biosystems (NASDAQ:TTOO) Now Covered by Analysts at StockNews.comSeptember 19, 2023 | benzinga.comWhy T2 Biosystems Stock Fell TodaySeptember 19, 2023 | msn.comT2 Biosystems stock sinks after rallying in prior session amid FDA newsSeptember 19, 2023 | finance.yahoo.comT2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat PanelSeptember 19, 2023 | americanbankingnews.comT2 Biosystems Target of Unusually Large Options Trading (NASDAQ:TTOO)September 18, 2023 | benzinga.comWhy T2 Biosystems Stock Is Cleared For Take OffSeptember 18, 2023 | msn.comWhy Is T2 Biosystems (TTOO) Stock Up 30% Today?September 7, 2023 | finance.yahoo.comT2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company ShowcaseAugust 28, 2023 | finance.yahoo.comT2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis ProgramsAugust 24, 2023 | finance.yahoo.comIs T2 Biosystems a Hidden Gem or a Value Trap? An In-Depth AnalysisAugust 24, 2023 | investorplace.comT2 Biosystems Preps to Resell 141 Million Shares of TTOO StockAugust 21, 2023 | investorplace.comTTOO Stock Alert: T2 Biosystems Seeks Approval for Reverse Stock SplitAugust 17, 2023 | proactiveinvestors.comT2 Biosystems shares slide after snapping winning streakAugust 16, 2023 | proactiveinvestors.comT2 Biosystems shares fly, again, as memestock buzz keeps goingAugust 16, 2023 | benzinga.comWhat's Going On With T2 Biosystems (TTOO) Stock?August 16, 2023 | msn.comT2 Biosystems stock climbs more than 4% premarket to continue rallySee More Headlines Receive TTOO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for T2 Biosystems and its competitors with MarketBeat's FREE daily newsletter. Email Address TTOO Company Calendar Last Earnings8/07/2023Today9/27/2023Next Earnings (Estimated)11/09/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TTOO CUSIPN/A CIK1492674 Webwww.t2biosystems.com Phone(781) 761-4646Fax781-357-3080Employees158Year FoundedN/APrice Target and Rating Average Stock Price Forecast$2.50 High Stock Price Forecast$2.50 Low Stock Price Forecast$2.50 Forecasted Upside/Downside+1,232.6%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,000,000.00 Net Margins-392.26% Pretax Margin-392.29% Return on EquityN/A Return on Assets-134.24% Debt Debt-to-Equity RatioN/A Current Ratio0.36 Quick Ratio0.30 Sales & Book Value Annual Sales$22.31 million Price / Sales2.81 Cash FlowN/A Price / Cash FlowN/A Book Value($5.14) per share Price / Book-0.04Miscellaneous Outstanding Shares333,580,000Free Float333,246,000Market Cap$62.58 million OptionableOptionable Beta0.27 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. John J. Sperzel III (Age 60)B.Sc., Pres, CEO & Chairman Comp: $865.5kMr. John M. Sprague CPA (Age 65)Chief Financial Officer Comp: $482.33kMr. Michael Terrence Gibbs Esq. (Age 52)Sr. VP, Gen. Counsel & Company Sec. Comp: $487.33kMs. Kelley J. Morgan (Age 47)Chief People Officer Dr. Aparna Jha Ahuja M.D. (Age 56)Chief Medical Officer & Chairman of Scientific Advisory Board Mr. Brett A. Giffin (Age 64)Chief Commercial Officer Dr. Roger Smith Ph.D. (Age 58)Sr. VP of Science R&D More ExecutivesKey CompetitorsBrainsWayNASDAQ:BWAYLucid DiagnosticsNASDAQ:LUCDInspireMDNYSE:NSPRDelcath SystemsNASDAQ:DCTHPro-DexNASDAQ:PDEXView All CompetitorsInsiders & InstitutionsGroup L.P. CrSold 6,338,211 sharesTotal: $1.90 M ($0.30/share)Group L.P. CrSold 10,401,466 sharesTotal: $3.85 M ($0.37/share)Citadel Advisors LLCBought 1,200 shares on 8/15/2023Ownership: 0.000%Acadian Asset Management LLCBought 953,656 shares on 8/7/2023Ownership: 0.329%Simplex Trading LLCBought 200 shares on 8/4/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions TTOO Stock - Frequently Asked Questions Should I buy or sell T2 Biosystems stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for T2 Biosystems in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TTOO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TTOO, but not buy additional shares or sell existing shares. View TTOO analyst ratings or view top-rated stocks. What is T2 Biosystems' stock price forecast for 2023? 1 Wall Street research analysts have issued 1-year price objectives for T2 Biosystems' stock. Their TTOO share price forecasts range from $2.50 to $2.50. On average, they predict the company's stock price to reach $2.50 in the next year. This suggests a possible upside of 1,232.6% from the stock's current price. View analysts price targets for TTOO or view top-rated stocks among Wall Street analysts. How have TTOO shares performed in 2023? T2 Biosystems' stock was trading at $1.42 at the start of the year. Since then, TTOO stock has decreased by 86.8% and is now trading at $0.1876. View the best growth stocks for 2023 here. When is T2 Biosystems' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023. View our TTOO earnings forecast. How were T2 Biosystems' earnings last quarter? T2 Biosystems, Inc. (NASDAQ:TTOO) posted its quarterly earnings data on Monday, August, 7th. The medical equipment provider reported ($0.08) EPS for the quarter. The medical equipment provider had revenue of $1.96 million for the quarter. When did T2 Biosystems' stock split? Shares of T2 Biosystems reverse split on Thursday, October 13th 2022. The 1-50 reverse split was announced on Thursday, October 13th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What guidance has T2 Biosystems issued on next quarter's earnings? T2 Biosystems issued an update on its second quarter 2023 earnings guidance on Thursday, July, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.00 million-$2.00 million, compared to the consensus revenue estimate of $2.70 million. What is John McDonough's approval rating as T2 Biosystems' CEO? 36 employees have rated T2 Biosystems Chief Executive Officer John McDonough on Glassdoor.com. John McDonough has an approval rating of 54% among the company's employees. This puts John McDonough in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of T2 Biosystems own? Based on aggregate information from My MarketBeat watchlists, some companies that other T2 Biosystems investors own include Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Tonix Pharmaceuticals (TNXP), OPKO Health (OPK), SCYNEXIS (SCYX), Biocept (BIOC), Heat Biologics (HTBX), NVIDIA (NVDA) and Vaxart (VXRT). What is T2 Biosystems' stock symbol? T2 Biosystems trades on the NASDAQ under the ticker symbol "TTOO." Who are T2 Biosystems' major shareholders? T2 Biosystems' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.33%), Citadel Advisors LLC (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Adrian M Jones, Alec Barclay, Brett A Giffin, Goldman Sachs & Co Llc, Group LP Cr, John J Sperzel III, John M Sprague, John Mcdonough and Michael Terrence Gibbs. View institutional ownership trends. How do I buy shares of T2 Biosystems? Shares of TTOO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is T2 Biosystems' stock price today? One share of TTOO stock can currently be purchased for approximately $0.19. How much money does T2 Biosystems make? T2 Biosystems (NASDAQ:TTOO) has a market capitalization of $62.58 million and generates $22.31 million in revenue each year. How many employees does T2 Biosystems have? The company employs 158 workers across the globe. How can I contact T2 Biosystems? T2 Biosystems' mailing address is 101 HARTWELL AVENUE, LEXINGTON MA, 02421. The official website for the company is www.t2biosystems.com. The medical equipment provider can be reached via phone at (781) 761-4646, via email at ir@t2biosystems.com, or via fax at 781-357-3080. This page (NASDAQ:TTOO) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding T2 Biosystems, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.